Protective effect of fluvastatin on influenza virus infection

Molecular Medicine Reports

Volumn 9, Issue 6, 2014, Pages 2221-2226

  Peng, Jing ^a,b   Zhang, Dingmei ^a   Ma, Yu ^a   Wang, Guoling ^c   Guo, Zhongmin ^a   Lu, Jiahai ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Fluvastatin; Influenza virus; Virus infection

Indexed keywords

FLUINDOSTATIN; GAMMA INTERFERON; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN; VIRUS RNA; ANTIVIRUS AGENT; CYTOKINE; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ANIMAL CELL; ARTICLE; CYTOTOXICITY; DRUG MECHANISM; HOST CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INFLUENZA A; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PROTEIN SYNTHESIS; VIRUS ATTACHMENT; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL SURVIVAL; DISEASE MODEL; DOG; DRUG EFFECTS; IC50; INFLUENZA VIRUS A H1N1; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; PHYSIOLOGY; TOXICITY; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; DOGS; FATTY ACIDS, MONOUNSATURATED; HUMANS; INDOLES; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INHIBITORY CONCENTRATION 50; MICE; ORTHOMYXOVIRIDAE INFECTIONS; RNA, VIRAL; VIRUS REPLICATION;

EID: 84899680709     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2076     Document Type: Article

References (35)

1. Kok J and Dwyer DE: How common was 2009 pandemic influenza A H1N1? Lancet Infect Dis 11: 423-424, 2011.
2. World Health Organization: Pandemic (H1N1) - update 112. http://wwwwhoint/csr/don/2010-08-06/en/indexhtml. Accessed November 10, 2011.
3. Memoli MJ, Morens DM and Taubenberger JK: Pandemic and seasonal influenza: therapeutic challenges. Drug Discov Today 13: 590-595, 2008.
4. Cox MM: Pandemic influenza: overview of vaccines and antiviral drugs. Yale J Biol Med 78: 321-328, 2005.
5. Podolec P and Kopeć G: Influenza vaccines for prevention of cardiovascular diseases. Kardiol Pol 65: 612-615, 2007 (In Polish).
6. Lambert LC and Fauci AS: Influenza vaccines for the future. N Engl J Med 363: 2036-2044, 2010.
7. Sugrue RJ, Tan BH, Yeo DS and Sutejo R: Antiviral drugs for the control of pandemic influenza virus. Ann Acad Med Singapore 37: 518-524, 2008.
8. Moss RB, Davey RT, Steigbigel RT and Fang F: Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. J Antimicrob Chemother 65: 1086-1093, 2010.
9. Fedson DS: Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 8: 571-576, 2008.
10. Tleyjeh IM, Kashour T, Hakim FA, et al: Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169: 1658-1667, 2009.
11. Zhou Q and Liao JK: Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 74: 818-826, 2010.
12. Corsini A, Ferri N and Cortellaro M: Are pleiotropic effects of statins real? Vasc Health Risk Manag 3: 611-613, 2007. (Pubitemid 350104116)
13. Terblanche M, Smith TS and Adhikari NK: Statins, bugs and prophylaxis: intriguing possibilities. Crit Care 10: 168, 2006.
14. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR and Katze MG: Into the eye of the cytokine storm. Microbiol Mol Biol Rev 76: 16-32, 2012.
15. Montoya CJ, Jaimes F, Higuita EA, et al: Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. Trials 10: 41, 2009.
16. Gower TL and Graham BS: Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob Agents Chemother 45: 1231-1237, 2001. (Pubitemid 32231005)
17. Frost FJ, Petersen H, Tollestrup K and Skipper B: Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131: 1006-1012, 2007. (Pubitemid 46608700)
18. Kwong JC, Li P and Redelmeier DA: Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS One 4: e8087, 2009.
19. Hayden F: Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48 (Suppl 1): S3-S13, 2009.
20. Nair P and Roguin A: Statins and the acute coronary syndrome: 'the early bird catches the worm'. Int J Clin Pract 60: 716-727, 2006. (Pubitemid 43811653)
21. Ye J, Wang C, Sumpter R Jr, Brown MS, Goldstein JL and Gale M Jr: Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Nat Acad Sci USA 100: 15865-15870, 2003. (Pubitemid 38021081)
22. del Real G, Jiménez-Baranda S, Mira E, et al: Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 200: 541-547, 2004. (Pubitemid 39121911)
23. Moncunill G, Negredo E, Bosch L, et al: Evaluation of the anti-HIV activity of statins. AIDS 19: 1697-1700, 2005. (Pubitemid 41502686)
24. Janssen NE, van Lelyveld SF, Hoepelman AI, Gras L, Groenwold RH and Oosterheert JJ: The effect of statin therapy on pneumonia in an HIV-infected population in the Netherlands. J Infect 67: 238-241, 2013.
25. Grau AC and George SM: Improved outcomes in community-acquired pneumonia with prior statin use. Am J Med 122: e15, author reply e17, 2009.
26. Chalmers JD, Singanayagam A, Murray MP and Hill AT: Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 121: 1002-1007, 2008.
27. Guo YF and Hu DY: Statin use and reduced prevalence of sepsis. Zhonghua Nei Ke Za Zhi 46: 798-800, 2007 (In Chinese).
28. Almog Y, Shefer A, Novack V, et al: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 110: 880-885, 2004. (Pubitemid 39096018)
29. Liu Z, Guo Z, Wang G, et al: Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur J Pharm Sci 38: 215-223, 2009.
30. Jin Y, Zhang G, Hu Y, et al: Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib. J Gene Med 13: 243-249, 2011.
31. Hui DS, Lee N and Chan PK: Adjunctive therapies and immunomodulatory agents in the management of severe influenza. Antiviral Res 98: 410-416, 2013.
32. Node K, Fujita M, Kitakaze M, Hori M and Liao JK: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839-843, 2003. (Pubitemid 37022126)
33. Radigan KA, Urich D, Misharin AV, et al: The effect of rosuvastatin in a murine model of influenza A infection. PLoS One 7: e35788, 2012.
34. Belser JA, Szretter KJ, Katz JM and Tumpey TM: Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice. Virology 439: 42-46, 2013.
35. Zarogiannis SG, Noah JW, Jurkuvenaite A, Steele C, Matalon S and Noah DL: Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1). Life Sci 90: 440-445, 2012.